Literature DB >> 33134203

Parvovirus B19 infection mimicking systemic lupus erythematosus, successfully treated with intravenous immune globulin.

Sare Gülfem Özlü1, Başak Alan2, Aysegül Şahiner3, Büşra Bulut4, Gülsüm İclal Bayhan5, Sonay İncesoy Özdemir6.   

Abstract

INTRODUCTION: Parvovirus B19 infection generally presents as a transient viral illness in children but rarely shows systemic lupus erythematosus-like symptoms. CASE REPORT: Here we present a 7-year-old girl with parvovirus B19 infection who had prolonged fever, rash, pancytopenia and hypocomplementemia making it difficult do differentiate from the first episode of systemic lupus erythematosus. Because she had severe progressive pancytopenia she was administered intravenous immune globulin treatment and her clinical course was dramatically improved. DISCUSSION: Parvovirus B19 infection can mimic systemic lupus erythematosus and it may be difficult to differentiate a recent parvovirus B19 infection and the first presentation of systemic lupus erythematosus. Absence of discoid lesions, alopecia, Raynaud phenomenon and autoimmune hemolytic anemia may help to distinguish parvovirus B19 infection from systemic lupus erythematosus.
CONCLUSIONS: Parvovirus B19 infection may cause a severe clinical picture resembling systemic lupus erythematosus even in otherwise healthy children. Intravenous immune globulin treatment might be considered in cases resistant to supportive management. GERMS.

Entities:  

Keywords:  Parvovirus B19; children; systemic lupus erythematosus

Year:  2020        PMID: 33134203      PMCID: PMC7572201          DOI: 10.18683/germs.2020.1211

Source DB:  PubMed          Journal:  Germs        ISSN: 2248-2997


  10 in total

1.  Hypocomplementemia is a diagnostic clue for parvovirus B19 infection in adults.

Authors:  Hideo Hashizume; Reiko Kageyama
Journal:  J Dermatol       Date:  2016-05-30       Impact factor: 4.005

2.  Human parvovirus B19 infection mimicking systemic lupus erythematosus.

Authors:  T Saeki; M Shibuya; H Sawada; S Miyamura; M Nakano; F Gejyo; M Arakawa
Journal:  Mod Rheumatol       Date:  2001-12       Impact factor: 3.023

3.  Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins.

Authors:  K Herzog-Tzarfati; E Shiloah; M Koren-Michowitz; S Minha; M J Rapoport
Journal:  Eur J Intern Med       Date:  2006-10       Impact factor: 4.487

Review 4.  Human parvovirus B19 infection: its relationship with systemic lupus erythematosus.

Authors:  S Trapani; M Ermini; F Falcini
Journal:  Semin Arthritis Rheum       Date:  1999-04       Impact factor: 5.532

5.  Parvovirus infection mimicking systemic lupus erythematosus in a pediatric population.

Authors:  T L Moore; R Bandlamudi; S M Alam; G Nesher
Journal:  Semin Arthritis Rheum       Date:  1999-04       Impact factor: 5.532

Review 6.  Lupus-like presentation of parvovirus B19 infection.

Authors:  Pascal Sève; Tristan Ferry; Martial Koenig; Pascal Cathebras; Hugues Rousset; Christiane Broussolle
Journal:  Semin Arthritis Rheum       Date:  2005-02       Impact factor: 5.532

7.  Parvovirus B19 infection can induce histiocytic necrotizing lymphadenitis (Kikuchi's disease) associated with systemic lupus erythematosus.

Authors:  O Meyer; M F Kahn; M Grossin; P Ribard; N Belmatoug; F Morinet; J C Fournet
Journal:  Lupus       Date:  1991-11       Impact factor: 2.911

8.  Pediatric parvovirus B19: spectrum of clinical manifestations.

Authors:  Monica N Valentin; Philip J Cohen
Journal:  Cutis       Date:  2013-10

9.  Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins.

Authors:  Jens Modrof; Andreas Berting; Björn Tille; Andreas Klotz; Christina Forstner; Sandra Rieger; Claudia Aberham; Matthias Gessner; Thomas R Kreil
Journal:  Transfusion       Date:  2007-09-27       Impact factor: 3.157

Review 10.  Infectious processes and systemic lupus erythematosus.

Authors:  Rebeca Illescas-Montes; Claudia Cristina Corona-Castro; Lucia Melguizo-Rodríguez; Concepción Ruiz; Víctor J Costela-Ruiz
Journal:  Immunology       Date:  2019-08-30       Impact factor: 7.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.